The ICAHN Medical School on Mount Sinai began the Drug Discovery Center for Small Molecular Molecular Molecular Molecular Molecular, a bold effort that utilizes Artificial Intelligence (AI) for the revolution in drug development. The new center will incorporate AI with traditional methods of discovery of drugs to identify and design new therapeutic small molecules with unprecedented speed and precision.
In contrast to the conventional discovery of drugs, which can last for years and cost billions, approaches to AI allow researchers to quickly browse a huge chemical landscape, including natural products, to identify promising candidates. Utilizing Mount Sinai’s global experience in mechanical learning, chemical biology and biomedical science, the Center aims to bring innovative treatments to patients faster for diseases with emergency diseases, including cancer and cancer.
“At Mount Sinai, we are committed to redefining the future of medical innovation,” says Avner Schlessinger, PhD, Professor drive the center. “By incorporating artificial intelligence with cutting -edge chemistry and biology, we can dramatically accelerate the discovery of drugs and develop new treatments for some of the most complex and pressing diseases.”
The AI Drug Discovery Center will focus on three basic areas: designing new drug -like molecules using genetically, optimization of existing compounds to enhance their efficacy and safety and predict the interactions targeted by medicines for medicines.
Experts in computing medicines in the new center could revolutionize the discovery process by turning traditional rational drug design approaches with forecasts driven by the c. By drawing up AI models in huge sets of molecular structures and biological activity, they can predict the properties of new compounds before the composition, possibly saving years of experimental work.
An important power of this strategy fueled by A is its ability to explore a chemical space on a scale far beyond human ability.
The huge combination capabilities in optimal drug design lead to high costs, time -consuming timetables and low success rates. AI effectively navigates this complex landscape, identifying the most promising candidates-an achievement that is unthinkable just a few years ago. ”
Ming-Ming Zhou, Phd, Dr. Harold and Golden Lamport Professor of Physiology and Biophysics and President of the Department of Pharmacological Sciences at the ICAHN School of Medicine on Mount Sinai
The AI small molecule discovery center will also promote partnerships with leading pharmaceutical companies, biotechnology companies and academic institutions to promote drug development. In addition, it provides practical training for the next generation of scientists through seminars, internship programs and hackathons discovery discovery.
The new center is based on other major recent Mount Sinai AI initiatives, including the launch of the new AI building and the recent announcement of the Center for Artificial Intelligence in Child Health.
“AI fundamentally reforms how we understand and aim at molecular diseases,” says Alexander Charney, MD, PhD, Vice President, the Windreich Mount Sinai Mount’s Department of Intelligence and Human Health. He is also director of Charles Bronfman’s personalized medicine. “By incorporating artificial intelligence with genetic knowledge, we can go beyond the conventional discovery of drugs to design precision therapeutically adapted to the underlying biology of neuropsychiatry and many other complex disorders.”
The Center is guided by a distinguished scientific advisory council consisting of leading experts in the discovery of drugs and mechanical learning:
- Jian Jin, PhD, Professor of Mount Sinai at Discovery Therapeutics and director of Mount Sinai Center for Therapeutics Discovery at ICAHN School of Medicine on Mount Sinai, a famous expert in synthetic chemistry and developing medicines with extensive experience covering both academic and industry.
- Dr. Zhou, who also serves as a co-director of the Discovery Institute and Professor of Oncology Sciences. His research focuses on the mechanisms of gene transcription on health and diseases, with a strong emphasis on epigenetic discovery.
- Marta Filizola, PhD, Sharon and Frederick Klingenstein-Nathan Kase, Professor MD and Dean of the Biomedical Sciences School, Leading Authority in the Computational Biophysics of Membrane Protein. With more than 25 years of experience, it has pioneering the use of AI and theoretical chemistry to promote the discovery and development of drugs.
- Girish Nadkarni, MD, MPH, CPH, President of the Department of Artificial Intelligence and Human Health of Windreich at the ICAHN Medical School on Mount Sinai, where he is also director of the Hasso Plattner Institute for Digital Health and Peace and Dr. Arthur M. Fishberg Professor of Medicine. A Trailblazer in AI and Digital Health, established several companies and has various patents related to AI.
The Center will initially focus on building an advanced AI infrastructure and on the start of basic drug discovery projects. Over the next two years, Mount Sinai expects to make significant discoveries in the design of drugs driven by AI, further enhancing his role as a leader in biomedical innovation.
“The launch of the Drug Discovery Center AI reflects our commitment to promote the boundaries of biomedical innovation,” said Eric J. Nestler, MD, director of the Friedman Brain Institute, Dean for Academic Affairs, Neuroscience at ICAHN School of Medicine in Mount Sinai. “By utilizing the power of AI, we transform how new medicines are discovered and developed, bringing hope to patients who need repetitions faster than ever.”
“We are at the dawn of a new era in the discovery of drugs,” Dr. Schlessinger added. “By combining AI, computational chemistry and biomedical research, we do not only do the discovery of drugs faster-we make it smarter, more effective and more adapted to the biological complexity of human disease.”
Learn more about the AI small molecule discovery center in: https://icahn.mssm.edu/ai-drug-disCovery-center.
Source:
